Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Lorlatinib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for lorlatinib and what is the scope of patent protection?

Lorlatinib is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lorlatinib has fifty-one patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for lorlatinib

International Patents:	51
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	44
Clinical Trials:	15
Patent Applications:	54
DailyMed Link:	lorlatinib at DailyMed

Recent Clinical Trials for lorlatinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
European Organisation for Research and Treatment of Cancer - EORTC	Phase 2
Intergroupe Francophone de Cancerologie Thoracique	Phase 2
National Cancer Institute (NCI)	Phase 2

See all lorlatinib clinical trials

Pharmacology for lorlatinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors Cytochrome P450 3A4 Inducers

Synonyms for lorlatinib

(10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
(10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-H][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile
1454846-35-5
2641AH
2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-
4cli
4clj
7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile
AK175603
AKOS027250753
BC600707
BCP10287
BDBM50018830
CHEMBL3286830
CS-3983
D11012
DB12130
EX-A828
FT-0700455
GTPL7476
HY-12215
J-690185
KB-334037
KS-00000T6C
Loratinib
Lorbrena (TN)
lorlantinib
Lorlatinib (JAN/USAN/INN)
Lorlatinib [USAN:INN]
Lorlatinib,PF-06463922
MFCD28144520
MolPort-035-789-724
NCGC00386417-02
NCGC00386417-13
OSP71S83EU
PF 06463922
PF-06463922
PF-6463922
PF06463922(Lorlatinib)
s7536
SCHEMBL15261807
UNII-OSP71S83EU
ZINC98208524

US Patents and Regulatory Information for lorlatinib

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No	Start Trial	Start Trial	Y	Y		Start Trial
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No	Start Trial	Start Trial				Start Trial
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No	Start Trial	Start Trial				Start Trial
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes	Start Trial	Start Trial	Y	Y		Start Trial
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for lorlatinib

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Mexico	2014010716	Start Trial
Peru	23392014	Start Trial
Japan	2015510879	Start Trial
Israel	234062	Start Trial
European Patent Office	2822953	Start Trial
Taiwan	I476199	Start Trial
Canada	2863892	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for lorlatinib

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822953	CA 2019 00041	Denmark	Start Trial	PRODUCT NAME: LORLATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1355 20190508
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.